Pharmafile Logo
Pharmafocus logo
Advanced Search

Erbitux

Showing 15 posts of 24 posts found.

Merck scores expanded NICE recommendation in head, neck and oral cancer

August 8, 2017
Manufacturing and Production, Sales and Marketing Erbitux, Merck, NICE, biotech, cetuximah, drugs, life sciences, pharma, pharmaceuticals

Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as …

News

BMS names Fouad Namouni as new oncology development head

July 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …

Appointment
sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

News
Merck image

Merck and Biocartis partner on new biomarker test for colorectal cancer

January 7, 2016
Research and Development BRAF mutations, Diagnostics, Erbitux, Merck, RAS metations, diagnostic tests, metastic colorectal cancer

Merck has signed a collaboration agreement with diagnostics company Biocartis for the development and commercialisation of a new test for …

News
erbitux-resized

Merck’s Erbitux approved for NHS Wales

January 5, 2016
Manufacturing and Production, Sales and Marketing Erbitux, Merck, cetuximab, colorectal cancer, metastatic colorectal cancer

The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS …

News

Merck KGaA’s sales climb but key drugs fall

May 19, 2015
Sales and Marketing Erbitux, Merck, Merck KGaA, Q1, Rebif

Merck KGaA encountered an uneven start to 2015, with robust sales in the first quarter offset by declines in key …

News
Galderma image

Merck and Galderma breach ABPI code

December 8, 2014
Medical Communications, Sales and Marketing ABPI, Erbitux, Galderma, PMCPA, merch

Merck Serono and Galderma will be named in advertisements as guilty of the most serious breach of the ABPI Code …

News
Erbitux image

Merck KGaA declines in Q2

August 7, 2013
Sales and Marketing Erbitux, Merck KGaA, Q2, Serono

Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …

News
Merck Serono image

Merck Serono censured over calls

June 25, 2013
Medical Communications, Sales and Marketing ABPI, Erbitux, Merck Serono, PMCPA

A Merck Serono medical representative has been accused of ‘harassing’ an anonymous health professional by requesting a meeting every month …

News
Zaltrap image

Sanofi’s Zaltrap data published

October 8, 2012
Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin

Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …

News
erbitux image

Erbitux fails in gastric cancer trial

July 6, 2012
Research and Development, Sales and Marketing Erbitux, Merck Serono, Roche, failure, gastric cancer

Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to …

News
Erbitux image

Merck KGaA’s colon cancer drug fails trial

May 16, 2012
Research and Development, Sales and Marketing Erbitux, Merck KGaA, Merck Serono, colon cancer

Merck KGaA has suffered a setback with key brand Erbitux as the colerectal cancer drug failed in a late-stage trial.  …

News

FDA grants priority review for Sanofi cancer drug

April 5, 2012
Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer

The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …

News

NICE confirms ‘no’ for colorectal cancer drugs

November 24, 2011
Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer

 

News

NICE rejects three bowel cancer drugs

September 5, 2011
Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer

NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023